Development
Boston Scientific Corporation
BSX
$102.09
-$0.74-0.72%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 86.67% | -14.01% | 124.29% | -25.53% |
| Total Depreciation and Amortization | 4.33% | 0.67% | 4.56% | -3.06% | 3.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 181.43% | -32.69% | -8.77% | 192.31% | -87.09% |
| Change in Net Operating Assets | 67.61% | -1,157.14% | 97.32% | -256.59% | 209.87% |
| Cash from Operations | 37.11% | 6.08% | 246.32% | -76.46% | 71.70% |
| Capital Expenditure | -40.53% | -32.87% | -28.83% | 47.64% | -41.33% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -100.00% | 50.00% | 100.00% |
| Cash Acquisitions | -- | 100.00% | -71.47% | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 187.50% | 85.19% | -5,300.00% | -104.55% | 540.00% |
| Cash from Investing | -434.52% | 76.55% | -73.55% | -164.48% | 18.67% |
| Total Debt Issued | -- | -200.00% | -- | -- | 100.00% |
| Total Debt Repaid | 100.00% | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -77.33% | 177.78% | -57.14% | 231.58% | -67.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 100.00% | 0.00% | -7.69% | 7.14% |
| Other Financing Activities | 88.89% | -157.14% | 94.07% | -2,260.00% | 94.38% |
| Cash from Financing | -6.25% | -62.79% | 162.32% | -7,000.00% | 100.50% |
| Foreign Exchange rate Adjustments | 180.00% | -66.67% | -- | -- | 150.00% |
| Miscellaneous Cash Flow Adjustments | -- | 200.00% | -- | -- | 200.00% |
| Net Change in Cash | -115.01% | 458.74% | 60.61% | -157.71% | 1,512.82% |